Pulmonary hypertension is a progressive disease, and its treatment often requires the use of specific drugs to relieve symptoms and delay the progression of the disease. Tasul Ambrisentan Tablets (Ambrisentan) is one of the targeted therapeutic drugs that can treat this disease. Patients are particularly concerned about its price, medication effects and contraindications for use in special populations.
How much is a box of Tasul Ambrisentan Tablets?
Drug prices often vary depending on region, specifications and brand differences. For example, Tasul Ambrisentan Tablets produced by Cipla Pharmaceuticals in India. However, there may be other specifications in different markets, and patients need to refer to the quotations of local pharmacies or medical institutions.
Price change factors
Drug pricing is affected by multiple factors such as production costs, import tariffs, supply chain costs and market competition. International exchange rate fluctuations may also lead to differences in actual expenditures when purchasing in different time periods.
Cost-effectiveness considerations
Although the price per box seems high, Ambrisentan reflects long-term value by improving the symptoms of pulmonary hypertension and improving the quality of life of patients. It is necessary to strictly follow the doctor's prescribed dosage to avoid waste or increased risk of side effects due to overdose.
In addition to paying attention to the price of the drug, patients need to understand its impact on physical indicators. As an endothelin receptor antagonist, Ambrisentan may have specific effects on the blood system.
Effects of Ambrisentan tablets on blood values
Hemoglobin level is a blood indicator that needs to be monitored during the use of this drug. Clinically, it is recommended to test the hemoglobin value as a baseline value one month before treatment, and then conduct regular rechecks.
Hemoglobin monitoring mechanism
Ambrisentan may indirectly cause hemoglobin fluctuations by affecting erythropoiesis or vasodilation. If hemoglobin decreases significantly and other causes are excluded, it is necessary to consider adjusting the treatment plan.
Precautions for patients with anemia
People with obvious anemia symptoms should not start Ambrisentan treatment directly. Doctors need to comprehensively evaluate the cause of anemia and pulmonary hypertension and develop individualized medication plans.
Different populations need to follow special guidelines when taking Ambrisentan.
Special population use of Taishule Ambrisentan Tablets
Patients with special physiological conditions or comorbidities need to undergo risk assessment before using Ambrisentan. This drug may cause fetal malformations, so it is contraindicated for pregnant women.
Protection of reproductive age groups
Women of childbearing age must take effective contraceptive measures during medication and within 1 month after stopping medication. If pregnancy is suspected, pregnancy testing should be performed immediately and an obstetrician should be consulted.
Adjustment for patients with liver and kidney dysfunction
Patients with mild to moderate renal dysfunction do not need to adjust the dose, but data for patients with severe renal dysfunction are insufficient. Patients with moderate to severe liver damage are contraindicated, and patients with mild liver damage need to monitor liver function carefully.
As an important choice for the treatment of pulmonary arterial hypertension, patients need to fully understand the price, blood system effects, and medication specifications for special populations of Taishule Ambrisentan Tablets. It is recommended to communicate with the medical team regularly, provide timely feedback on physical changes, and jointly develop the best management plan. Regular follow-up should be maintained during medication, and do not adjust the dose or interrupt treatment on your own.
